Cargando…
Autoimmune Diabetes and Thyroiditis Complicating Treatment with Nivolumab
Programmed cell death-1 (PD-1) ligand inhibitors have gained popularity in the treatment of advanced non-small-cell lung cancer. The immune system is regulated by stimulatory and inhibitory signaling and aims to achieve the balance between activation and inhibition. Treatment with immune checkpoint...
Autores principales: | Li, Li, Masood, Awais, Bari, Shahla, Yavuz, Sahzene, Grosbach, Alan B. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
S. Karger AG
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5465653/ https://www.ncbi.nlm.nih.gov/pubmed/28611636 http://dx.doi.org/10.1159/000456540 |
Ejemplares similares
-
Autoimmune Hemolytic Anemia as a Complication of Nivolumab Therapy
por: Palla, Amruth R., et al.
Publicado: (2016) -
Hypothyroidism: Cardiovascular Endpoints of Thyroid Hormone Replacement
por: Stamatouli, Angeliki, et al.
Publicado: (2020) -
Case Report: Nivolumab-Induced Autoimmune Pancreatitis
por: Goyal, Preeya, et al.
Publicado: (2021) -
Thyroid Hormone Action and Energy Expenditure
por: Yavuz, Sahzene, et al.
Publicado: (2019) -
Nivolumab-induced autoimmune diabetes mellitus and hypothyroidism in a patient with rectal neuroendocrine tumor
por: Haque, Waqas, et al.
Publicado: (2020)